Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

Function Health / Private Capital Markets

<ul><li>Sacra estimates that Function Health hit a $100M revenue run rate in February 2025, up approximately 450% year-over-year.</li><li>In November 2025, Function Health raised a $298M Series B led by Redpoint Ventures at a $2.5B valuation.</li><li>Function Health has begun expanding beyond blood testing into other diagnostic realms.</li></ul>

Sacra estimates that Function Health hit a $100M revenue run rate in February 2025, up approximately 450% year-over-year.In November 2025, Function Health raised a $298M Series B led by Redpoint Ventures at a $2.5B valuation.Function Health has begun expanding beyond blood testing into other diagnostic realms.

<ul><li>Sacra estimates that Whoop hit $1.1B in annualized bookings in 2025, up 103% YoY.</li><li>In March 2026, Whoop closed a $575M Series G round, valuing the company at $10.1B.</li><li>The FDA issued a warning letter over Whoop&#39;s Blood Pressure Insights feature for unauthorized marketing.</li></ul>

Sacra estimates that Whoop hit $1.1B in annualized bookings in 2025, up 103% YoY.In March 2026, Whoop closed a $575M Series G round, valuing the company at $10.1B.The FDA issued a warning letter over Whoop&#39;s Blood Pressure Insights feature for unauthorized marketing.

<ul><li>Sacra estimates that Ro hit $598M in annualized revenue in 2024, up 66% YoY from $360M in 2023.</li><li>In November 2025, the Trump administration announced TrumpRx, a federal direct purchasing platform using tariff threats to extract Most Favored Nation (MFN) pricing from pharmaceutical manufacturers &amp; bringing the cost of GLP-1s like Ozempic down to $350/month for cash payers (from $1,350/month).</li><li>TrumpRx threatens to commoditize away their pricing advantage.</li></ul>

Sacra estimates that Ro hit $598M in annualized revenue in 2024, up 66% YoY from $360M in 2023.In November 2025, the Trump administration announced TrumpRx, a federal direct purchasing platform using tariff threats to extract Most Favored Nation (MFN) pricing from pharmaceutical manufacturers &amp; bringing the cost of GLP-1s like Ozempic down to $350/month for cash payers (from $1,350/month).TrumpRx threatens to commoditize away their pricing advantage.

<ul><li>Sacra estimates that Hone Health hit $113.5M in annual recurring revenue (ARR) in September 2025, up from $69.7M at the end of 2024.</li><li>Hone Health closed a $33 million Series A in January 2025 led by Tribe Capital.</li><li>Hone&#39;s expansion from testosterone therapy into women&#39;s hormone replacement therapy more than triples the addressable market, with 3.3 million U.S. women entering menopause annually.</li></ul>

Sacra estimates that Hone Health hit $113.5M in annual recurring revenue (ARR) in September 2025, up from $69.7M at the end of 2024.Hone Health closed a $33 million Series A in January 2025 led by Tribe Capital.Hone&#39;s expansion from testosterone therapy into women&#39;s hormone replacement therapy more than triples the addressable market, with 3.3 million U.S. women entering menopause annually.

<ul><li>Superpower closed a $30 million Series A in April 2025 led by Forerunner Ventures at a post-money valuation exceeding $300 million.</li><li>Superpower operates a B2C subscription model that bundles diagnostic testing, AI-powered analytics, and clinical consultations into annual memberships.</li><li>The June 2025 acquisition of Base adds 90,000 nutrition-focused users and proprietary diet-hormone datasets, enabling expansion into personalized meal planning and targeted supplement recommendations.</li></ul>

Superpower closed a $30 million Series A in April 2025 led by Forerunner Ventures at a post-money valuation exceeding $300 million.Superpower operates a B2C subscription model that bundles diagnostic testing, AI-powered analytics, and clinical consultations into annual memberships.The June 2025 acquisition of Base adds 90,000 nutrition-focused users and proprietary diet-hormone datasets, enabling expansion into personalized meal planning and targeted supplement recommendations.

United States

Platform providing personalized health insights through comprehensive blood test analysis and genetic testing

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Function Health (HEALTH US)

Primer: Function Health - 22 Mar 2026

Platform providing personalized health insights through comprehensive blood test analysis and genetic testing

Sacra

Primer: Whoop - 31 May 2026

Wearable device and app tracking recovery, strain, and sleep for performance optimization

Sacra

Ro Vs TrumpRx

TL;DR: D2C telehealth platforms like Ro and Hims & Hers scaled from high-margin ED generics to even more lucrative GLP-1s, but Trump's TrumpRx...

Sacra

Primer: Hone Health - 19 Oct 2025

Telehealth service for men's testosterone therapy with mail-order prescriptions and lab monitoring

Sacra

Primer: Superpower - 19 Oct 2025

Digital clinic offering personalized, preventative, and longevity-focused medicine through comprehensive diagnostics and tailored health strategies

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)